CARSGEN-B (02171) announced the presentation of long-term follow-up update results for Seicarez® (zevor-cel injection, product code: CT053, a BCMA-targeted autologous CAR-T cell product) in a poster session at the 22nd International Myeloma Society Annual Meeting.

The updated results from Seicarez® Phase I clinical trial were presented in a poster session on the morning of September 17, 2025 (Toronto time) at the 22nd IMS Annual Meeting, titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma."

Seicarez® is a fully human anti-BCMA autologous CAR-T cell product for treating multiple myeloma (MM). The National Medical Products Administration approved Seicarez® for marketing on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent).

Zevor-cel injection received Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug status from the U.S. FDA in 2019.